May 12, 2021 / 02:30PM GMT
Unidentified Analyst -
Welcome to the 7th Emerging Growth Conference. I am [Ana Berry.] It's been a great morning so far, and we have some fantastic presentations coming up for you today. Let's start with AzurRx Biopharma, Inc. It trades on the NASDAQ under the symbol AZRX and is a clinical stage biopharmaceutical company specializing in the development of targeted nonsystemic therapies for gastrointestinal diseases.
Joining us today, we have Martin Krusin, SVP of Corporate Development; and we have Dan Schneiderman, the CFO. Welcome, Martin.
Martin Krusin - AzurRx BioPharma, Inc. - SVP of Corporate Development
Ana. Pleasure to be here.
Unidentified Analyst -
Yes. We're happy to hear your presentation. So the floor is yours, whenever you're ready.
Martin Krusin - AzurRx BioPharma, Inc. - SVP of Corporate Development
Thank you very much, and thank you for having us participate in this year's Emerging Growth Conference. So we're a AzurRx Biopharma. And as Ana said, we are a
AzurRx BioPharma Inc Emerging Growth Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot